Velarion · Company Intelligence
Compensation Brief
Fiscal year 2022 · Filings through 2026-04-30

Karuna Therapeutics (KRTX)

CEO Steven Paul was paid $11,224,103 in fiscal year 2022, ↓ down 14.6% from fiscal year 2021, the 69th percentile of its disclosed peer group (SEC filing 0000950170-23-014979 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$11,224,103 ↓
Steven Paul total, FY2022
69th
CEO pay percentile vs peers
27:1
CEO-to-median pay ratio
65.16%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2022

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Steven Paul$700,000$0$0$9,905,953$609,000$0$9,150$11,224,103
President and Chief Executive Officer
Andrew Miller500,000004,939,490326,25009,1505,774,890
Chief Operating Officer
Stephen Brannan470,000003,661,629272,60009,1504,413,379
Chief Medical Officer
Troy Ignelzi460,000003,270,515266,80009,1504,006,465
Chief Financial Officer
Charmaine Lykins475,000000275,50009,150759,650
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2022 totalFY2021 totalFY2020 totalΔ FY2021→2022
Steven Paul$11,224,103$13,136,960$8,902,241↓ −1,912,857
Andrew Miller5,774,8905,722,1684,662,146↑ +52,722
Stephen Brannan4,413,3794,523,7983,492,833↓ −110,419
Troy Ignelzi4,006,4654,513,5173,751,661↓ −507,052
Charmaine Lykins759,6505,832,673—↓ −5,073,023

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Karuna Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper KRTX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against KRTX
1 company names KRTX as a compensation peer

The list of companies that name KRTX as a peer is temporarily unavailable — recheck shortly.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jason Parker BrownChief Financial Officer2023-09-29A7,696$0$0Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2023-09-29A4,49600CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D1,744174303,055CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D3,256173563,158CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09A5,000132658,200CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D5,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D5,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D2,245180404,280CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D808179144,551CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D26517746,942CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D40117670,452CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08A5,000132658,200CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D1,281174223,035CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D10,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D9920420,214CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D3,969203804,675CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D2,116202426,861CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D1,565200313,172CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08A10,0001321,316,400CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D2,251204458,754CommonForm 4 ↗
Bill MeuryDirector2023-12-28D8,6943162,749,912CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2023-12-28D3,8283161,210,796CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D9,69600Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D5,30400Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D15,0003174,752,150CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08A9,6961121,085,661CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08A5,304132698,219CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D5,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D818317258,946CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D4,1823161,321,721CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08A5,000112559,850CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-09D1,046317331,728CommonForm 4 ↗
Andrew MillerPresident of R&D2024-02-09D1,011317320,629CommonForm 4 ↗
Steven PaulDirector2024-02-09D804317254,981CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-13A10,30600Derivative, Class A CommonForm 4 ↗
Bill MeuryDirector2024-02-13A38,68800Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-02-13A15,85500Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-02-13A10,30600Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-02-13D27831888,404CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-02-13A10,30600Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-02-23D27,51000Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-02-23A4,008100399,678CommonForm 4 ↗
Steven PaulDirector2024-02-23A27,5107199,998CommonForm 4 ↗
Steven PaulDirector2024-02-23D4,00800Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-02-29A47,37831514,932,598CommonForm 4 ↗
Steven PaulDirector2024-03-01A30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-01D30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-01A30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-01D30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-04A30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-04D30,30400CommonForm 4 ↗
Dividend-equivalent accruals2024-03-08—1,791——1 insider, 1 accrual row
Stephen BrannanChief Medical Officer2024-03-08D3,20900Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D10031931,896CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D4,9003181,559,817CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08A1,791112200,538CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08A3,209132422,433CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D17,3501432,476,539Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D37,8132188,244,368Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D12,8371982,546,347Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D50,00023011,514,000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D6,3623212,040,930Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D4,6773251,517,920Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D10,3063303,400,980Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D6,4873302,140,710CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D36,11733011,918,610CommonForm 4 ↗
Steven PaulDirector2024-03-18D22,8001433,254,472Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D146,90021832,028,607Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D135,99223031,316,238Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D71,12131022,046,088Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D15,2053214,877,764Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D87,49432128,068,075Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D449,463321144,187,730Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D757,045323244,321,133Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D136,09432343,952,918Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D35,87733011,839,410CommonForm 4 ↗
Steven PaulDirector2024-03-18D30,30433010,000,320CommonForm 4 ↗
Steven PaulDirector2024-03-18D33,88233011,181,060CommonForm 4 ↗
Steven PaulDirector2024-03-18D10,0003303,300,000CommonForm 4 ↗
Steven PaulDirector2024-03-18D8,5503302,821,500CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D976137133,527Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D25,0002436,083,750Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D990330326,700CommonForm 4 ↗
Denice TorresDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Denice TorresDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Denice TorresDirector2024-03-18D25,0002265,643,500Derivative, Class A CommonForm 4 ↗
Denice TorresDirector2024-03-18D990330326,700CommonForm 4 ↗
Steven PaulDirector2024-03-18D2,046330675,180CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D13,0002453,186,820Derivative, Class A CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D29,9371384,126,815Derivative, Class A CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D10,3063303,400,980Derivative, Class A CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D8,8283302,913,240CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D5,0003301,650,000CommonForm 4 ↗
Bill MeuryDirector2024-03-18D63,0651378,627,923Derivative, Class A CommonForm 4 ↗
Bill MeuryDirector2024-03-18D38,68833012,767,040Derivative, Class A CommonForm 4 ↗
Bill MeuryDirector2024-03-18D19,0373306,282,210CommonForm 4 ↗
Bill MeuryDirector2024-03-18D10,3423303,412,860CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D7,6961611,238,363Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D7,100138981,291Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D10,3122182,248,325Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D6,5621981,301,638Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D3,281230755,549Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D10,3063303,400,980Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D7,1583302,362,140CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D14,0093304,622,970CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D25,1001433,582,774Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D73,25021815,970,698Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D66,90019813,270,284Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D70,00023016,119,600Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D231,99232174,423,034Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D11,5783233,736,568Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D47,81732715,639,984Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D15,8553305,232,150Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D9,4123303,105,960CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D13,9773304,612,410CommonForm 4 ↗
Steven PaulDirector2024-03-18D161,85019832,104,566Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D616,703314193,644,742Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D30,30433010,000,320CommonForm 4 ↗
James HealyDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D12,5002322,905,125Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D8,0253302,648,250CommonForm 4 ↗
James HealyDirector2024-03-18D1,372,441330452,905,530CommonForm 4 ↗
James HealyDirector2024-03-18D683330225,390CommonForm 4 ↗
James HealyDirector2024-03-18D990330326,700CommonForm 4 ↗
James HealyDirector2024-03-18D32,50033010,725,000CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D12,5002322,905,125Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D16,2503145,102,500Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D19,8933236,420,068Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D990330326,700CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D990330326,700CommonForm 4 ↗
Atul PandeDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D12,5002322,905,125Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D990330326,700CommonForm 4 ↗
Denice TorresDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D25,0002355,886,000Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D990330326,700CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 164 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jason Parker BrownChief Financial Officer2023-09-29A7,696$0$0Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2023-09-29A4,49600CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D1,744174303,055CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D3,256173563,158CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09A5,000132658,200CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D5,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-10-09D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D5,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D2,245180404,280CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D808179144,551CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D26517746,942CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D40117670,452CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08A5,000132658,200CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-11-08D1,281174223,035CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D10,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D9920420,214CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D3,969203804,675CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D2,116202426,861CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D1,565200313,172CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08A10,0001321,316,400CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2023-12-08D2,251204458,754CommonForm 4 ↗
Bill MeuryDirector2023-12-28D8,6943162,749,912CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2023-12-28D3,8283161,210,796CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D9,69600Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D5,30400Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D15,0003174,752,150CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08A9,6961121,085,661CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08A5,304132698,219CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-01-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D5,00000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D818317258,946CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D4,1823161,321,721CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08A5,000112559,850CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-09D1,046317331,728CommonForm 4 ↗
Andrew MillerPresident of R&D2024-02-09D1,011317320,629CommonForm 4 ↗
Steven PaulDirector2024-02-09D804317254,981CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-02-13A10,30600Derivative, Class A CommonForm 4 ↗
Bill MeuryDirector2024-02-13A38,68800Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-02-13A15,85500Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-02-13A10,30600Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-02-13D27831888,404CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-02-13A10,30600Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-02-23D27,51000Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-02-23A4,008100399,678CommonForm 4 ↗
Steven PaulDirector2024-02-23A27,5107199,998CommonForm 4 ↗
Steven PaulDirector2024-02-23D4,00800Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-02-29A47,37831514,932,598CommonForm 4 ↗
Steven PaulDirector2024-03-01A30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-01D30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-01A30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-01D30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-04A30,30400CommonForm 4 ↗
Steven PaulDirector2024-03-04D30,30400CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D1,79100Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D3,20900Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D2,50000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D10031931,896CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08D4,9003181,559,817CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08A1,791112200,538CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08A3,209132422,433CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-08A2,500513,625CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D17,3501432,476,539Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D37,8132188,244,368Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D12,8371982,546,347Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D50,00023011,514,000Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D6,3623212,040,930Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D4,6773251,517,920Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D10,3063303,400,980Derivative, Class A CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D6,4873302,140,710CommonForm 4 ↗
Stephen BrannanChief Medical Officer2024-03-18D36,11733011,918,610CommonForm 4 ↗
Steven PaulDirector2024-03-18D22,8001433,254,472Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D146,90021832,028,607Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D135,99223031,316,238Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D71,12131022,046,088Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D15,2053214,877,764Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D87,49432128,068,075Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D449,463321144,187,730Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D757,045323244,321,133Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D136,09432343,952,918Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D35,87733011,839,410CommonForm 4 ↗
Steven PaulDirector2024-03-18D30,30433010,000,320CommonForm 4 ↗
Steven PaulDirector2024-03-18D33,88233011,181,060CommonForm 4 ↗
Steven PaulDirector2024-03-18D10,0003303,300,000CommonForm 4 ↗
Steven PaulDirector2024-03-18D8,5503302,821,500CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D976137133,527Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D25,0002436,083,750Derivative, Class A CommonForm 4 ↗
Christopher J. CoughlinDirector2024-03-18D990330326,700CommonForm 4 ↗
Denice TorresDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Denice TorresDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Denice TorresDirector2024-03-18D25,0002265,643,500Derivative, Class A CommonForm 4 ↗
Denice TorresDirector2024-03-18D990330326,700CommonForm 4 ↗
Steven PaulDirector2024-03-18D2,046330675,180CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D13,0002453,186,820Derivative, Class A CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D29,9371384,126,815Derivative, Class A CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D10,3063303,400,980Derivative, Class A CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D8,8283302,913,240CommonForm 4 ↗
William P. Kane JrChief Commercial Officer2024-03-18D5,0003301,650,000CommonForm 4 ↗
Bill MeuryDirector2024-03-18D63,0651378,627,923Derivative, Class A CommonForm 4 ↗
Bill MeuryDirector2024-03-18D38,68833012,767,040Derivative, Class A CommonForm 4 ↗
Bill MeuryDirector2024-03-18D19,0373306,282,210CommonForm 4 ↗
Bill MeuryDirector2024-03-18D10,3423303,412,860CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D7,6961611,238,363Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D7,100138981,291Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D10,3122182,248,325Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D6,5621981,301,638Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D3,281230755,549Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D10,3063303,400,980Derivative, Class A CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D7,1583302,362,140CommonForm 4 ↗
Jason Parker BrownChief Financial Officer2024-03-18D14,0093304,622,970CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D25,1001433,582,774Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D73,25021815,970,698Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D66,90019813,270,284Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D70,00023016,119,600Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D231,99232174,423,034Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D11,5783233,736,568Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D47,81732715,639,984Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D15,8553305,232,150Derivative, Class A CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D9,4123303,105,960CommonForm 4 ↗
Andrew MillerPresident of R&D2024-03-18D13,9773304,612,410CommonForm 4 ↗
Steven PaulDirector2024-03-18D161,85019832,104,566Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D616,703314193,644,742Derivative, Class A CommonForm 4 ↗
Steven PaulDirector2024-03-18D30,30433010,000,320CommonForm 4 ↗
James HealyDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D12,5002322,905,125Derivative, Class A CommonForm 4 ↗
James HealyDirector2024-03-18D8,0253302,648,250CommonForm 4 ↗
James HealyDirector2024-03-18D1,372,441330452,905,530CommonForm 4 ↗
James HealyDirector2024-03-18D683330225,390CommonForm 4 ↗
James HealyDirector2024-03-18D990330326,700CommonForm 4 ↗
James HealyDirector2024-03-18D32,50033010,725,000CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D12,5002322,905,125Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D16,2503145,102,500Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D19,8933236,420,068Derivative, Class A CommonForm 4 ↗
Jeffrey M. JonasDirector2024-03-18D990330326,700CommonForm 4 ↗
Laurie OlsonDirector2024-03-18D990330326,700CommonForm 4 ↗
Atul PandeDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D12,5002322,905,125Derivative, Class A CommonForm 4 ↗
Atul PandeDirector2024-03-18D990330326,700CommonForm 4 ↗
Denice TorresDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D1,90492175,739Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D5,0002271,135,200Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D8,5002021,716,915Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D25,0002355,886,000Derivative, Class A CommonForm 4 ↗
David E. WheadonDirector2024-03-18D990330326,700CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2022

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Troy IgnelziOPTION2022-02-16——48,500—$3,270,515
Stephen BrannanOPTION2022-02-16——54,300—3,661,629
Andrew MillerOPTION2022-02-16——73,250—4,939,490
Steven PaulOPTION2022-02-16——146,900—9,905,953
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Troy Ignelzi$0$0$3,270,5150.0%
Stephen Brannan003,661,6290.0%
Andrew Miller004,939,4900.0%
Steven Paul009,905,9530.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2022

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Stephen BrannanOption15,62599.72—
Steven PaulOption43,75099.72—
Andrew MillerOption37,631131.64—
Stephen BrannanOption28,884131.64—
Troy IgnelziOption48,500111.97—
Stephen BrannanOption11,3629.2—
Troy IgnelziOption17,18799.72—
Steven PaulOption146,900111.97—
Steven PaulOption91,040131.64—
Troy IgnelziOption34,2249.2—
Troy IgnelziOption29,053131.64—
Andrew MillerOption21,87599.72—
Andrew MillerOption73,250111.97—
Stephen BrannanOption54,300111.97—
Charmaine LykinsOption56,250125.52—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation philosophy is performance-based, focusing on aligning the financial interests of executive officers with those of shareholders by placing a substantial portion of total compensation 'at risk' through variable pay tied to pre-set, objective financial or operating goals and stock price appreciation. The program aims to link pay to the achievement of corporate and strategic goals, promote an ownership culture through equity, and provide market-competitive compensation to attract and retain talent.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20232023-06-2020,307,72610,859,879413,45165.16%Passed
20222022-06-1521,124,0635,639,878414,02778.93%Passed
20202020-06-15—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20232023-06-2065.16%a
20222022-06-1578.93%b
20202020-06-15—c

a. Approved under the standard stated in the filing — “As a result, such "broker non-votes" and abstentions will have no effect on the voting on Proposal 2.”.

b. Approved under the standard stated in the filing — “As a result, such “broker non-votes” and abstentions will have no effect on the voting on Proposal 2.”.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)27 : 1
CEO total compensation$11,224,103
Median employee compensation—
08

Director compensation — fiscal year 2022

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Christopher J. CoughlinIndependent · Board Chair · Audit (Chair) · Compensation$89,042$0$284,104—$0$373,145
Laurie OlsonIndependent · Audit · Nominating and Corporate Governance (Chair)61,0000284,104—0345,104
Atul Pande, M.DIndependent · Compensation (Chair) · Nominating and Corporate Governance60,5000284,104—0344,604
James Healy, M.D., Ph.DIndependent · Audit52,0000284,104—0336,104
Denice TorresIndependent · Compensation49,2500284,104—0333,354
David Wheadon, M.DIndependent · Nominating and Corporate Governance47,0000284,104—0331,104
Jeffrey Jonas, M.DNot independent42,5000284,104—0326,604
Steven Paul, M.DEmployee director000—00
Bill MeuryEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2022
Cash retainers and fees$401,292
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$401,292

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2022

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Karuna Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Karuna Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1TG Therapeutics, Inc.2025Michael Weiss$875,000$23,550,000$0$1,146,250$25,571,250
2Rhythm Pharmaceuticals, Inc.2025David Meeker807,6928,274,7857,688,560759,48817,544,525
3Biohaven Pharmaceutical Holding Company Ltd.2025Vlad Coric920,4002,202,4809,900,043013,500,438
4Mirati Therapeutics, Inc.2022David Meek749,4236,043,8854,233,427438,98511,937,371
5Cerevel Therapeutics Holdings, Inc.2022N. Anthony Coles642,735010,085,985496,70611,225,426
6Karuna Therapeutics2022Steven Paul700,00009,905,953609,00011,224,103
7Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
8Axsome Therapeutics, Inc.2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
9Intra-Cellular Therapies, Inc.2023Sharon Mates891,6537,749,9840010,086,413
10Acadia Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
11Sage Therapeutics, Inc.2024Barry Greene830,7123,164,3642,669,263431,9707,112,589
12Arvinas, Inc.2025John Houston706,2362,685,8402,671,051457,0006,534,127
13Allakos Inc.2023Robert Alexander805,4602,171,3402,623,519684,6416,299,426
14Prothena Corporation plc2025Gene Kinney692,973961,8003,809,738415,7845,896,045
15Denali Therapeutics Inc.2025Ryan Watts718,0001,151,8672,180,00304,751,515
16Kodiak Sciences Inc.2025Victor Perlroth792,4970923,032772,8242,499,221
17Alector, Inc.2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
—BioXcel Therapeutics, Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Karuna Therapeutics145%Option 100not disclosedAon
Acadia Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Alector, Inc.80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allakos Inc.not disclosedOptions 55 · RSU 45NoCompensia
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
Arvinas, Inc.108%Options 50 · RSU 50not disclosedAon (Aon's Human Capital Solutions practice, a division of Aon plc)
Axsome Therapeutics, Inc.150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Biohaven Pharmaceutical Holding Company Ltd.not disclosednot disclosednot disclosedAon
BioXcel Therapeutics, Inc.not disclosednot disclosednot disclosedRadford, a part of Aon plc
Cerevel Therapeutics Holdings, Inc.128.8%Options 100not disclosedPay Governance LLC
Denali Therapeutics Inc.145%not disclosednot disclosedAlpine Rewards
Intra-Cellular Therapies, Inc.not disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Kodiak Sciences Inc.150%Options 100not disclosedCompensia, Inc.
Mirati Therapeutics, Inc.not disclosedOption 50 · RSU 50not disclosedAon Human Capital Solutions and Alpine Rewards
Prothena Corporation plc100%not disclosednot disclosedPay Governance LLC
Rhythm Pharmaceuticals, Inc.120%Options 50 · RSU 50NoPay Governance
Sage Therapeutics, Inc.80%not disclosedYes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology IndexAlpine Rewards
TG Therapeutics, Inc.131%RSU 100NoCompensia, Inc.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Karuna Therapeutics in fiscal 2022?
As disclosed, Steven Paul (President and Chief Executive Officer) was the highest-paid executive at Karuna Therapeutics in fiscal 2022, with total compensation of $11,224,103.
How does Karuna Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Steven Paul's total compensation ranked at the 69th percentile of Karuna Therapeutics's disclosed peer group.
What is Karuna Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Karuna Therapeutics's CEO-to-median employee pay ratio was 27:1.
How did shareholders vote on Karuna Therapeutics's executive compensation?
As disclosed, 65.16% of shareholders supported Karuna Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Karuna Therapeutics spend in total on board compensation for fiscal 2022?
As disclosed, Karuna Therapeutics reported total board compensation of $401,292 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Steven PaulDEF 14A2023-04-270000950170-23-014979Section “Executive Compensation”. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694
2Section 01, Andrew MillerDEF 14A2023-04-270000950170-23-014979Section “Executive Compensation”. As printed: 5,774,890. Filing ↗machine: r8 · c25 · span 921070–921079
3Section 01, Stephen BrannanDEF 14A2023-04-270000950170-23-014979Section “Executive Compensation”. As printed: 4,413,379. Filing ↗machine: r11 · c25 · span 953156–953165
4Section 01, Troy IgnelziDEF 14A2023-04-270000950170-23-014979Section “Executive Compensation”. As printed: 4,006,465. Filing ↗machine: r5 · c25 · span 888985–888994
5Section 01, Charmaine LykinsDEF 14A2023-04-270000950170-23-014979Section “Executive Compensation”. As printed: 759,650. Filing ↗machine: r14 · c25 · span 985148–985155
6Section 03, Troy Ignelzi OPTIONDEF 14A2023-04-270000950170-23-014979Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r3 · c5 · span 794519–794525
7Section 03, Stephen Brannan OPTIONDEF 14A2023-04-270000950170-23-014979Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r5 · c5 · span 800520–800526
8Section 03, Andrew Miller OPTIONDEF 14A2023-04-270000950170-23-014979Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r4 · c5 · span 797519–797525
9Section 03, Steven Paul OPTIONDEF 14A2023-04-270000950170-23-014979Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. Filing ↗machine: t16 · r2 · c5 · span 791526–791533
10Section 07, pay ratioDEF 14A2023-04-270000950170-23-014979Section “CEO Pay Ratio”. As printed: 27 : 1. Filing ↗
11Section 08, Christopher J. CoughlinDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 373,145. Filing ↗machine: span 1862829–1863168
12Section 08, Laurie OlsonDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 345,104. Filing ↗machine: span 1884037–1884376
13Section 08, Atul Pande, M.DDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 344,604. Filing ↗machine: span 1891104–1891443
14Section 08, James Healy, M.D., Ph.DDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 336,104. Filing ↗machine: span 1869904–1870243
15Section 08, Denice TorresDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 333,354. Filing ↗machine: span 1898168–1898507
16Section 08, David Wheadon, M.DDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 331,104. Filing ↗machine: span 1905238–1905577
17Section 08, Jeffrey Jonas, M.DDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 326,604. Filing ↗machine: span 1876974–1877313
18Section 08, Steven Paul, M.DDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 0. Filing ↗
19Section 08, Bill MeuryDEF 14A2023-04-270000950170-23-014979Section “Director Compensation”. As printed: 0. Filing ↗
20Section 02, Jason Parker Brown 2023-09-29Form 42023-10-030000950170-23-051666Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Jason Parker Brown 2023-09-29Form 42023-10-030000950170-23-051666Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Stephen Brannan 2023-10-09Form 42023-10-100000950170-23-052671Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Stephen Brannan 2023-10-09Form 42023-10-100000950170-23-052671Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Stephen Brannan 2023-10-09Form 42023-10-100000950170-23-052671Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Stephen Brannan 2023-10-09Form 42023-10-100000950170-23-052671Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Stephen Brannan 2023-10-09Form 42023-10-100000950170-23-052671Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Stephen Brannan 2023-10-09Form 42023-10-100000950170-23-052671Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Stephen Brannan 2023-11-08Form 42023-11-130000950170-23-063121Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Stephen Brannan 2023-12-08Form 42023-12-120000950170-23-069766Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Bill Meury 2023-12-28Form 42023-12-290000950170-23-073877Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, William P. Kane Jr 2023-12-28Form 42023-12-290000950170-23-073878Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Stephen Brannan 2024-01-08Form 42024-01-090000950170-24-003372Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Stephen Brannan 2024-02-08Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Stephen Brannan 2024-02-08Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Stephen Brannan 2024-02-08Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Stephen Brannan 2024-02-08Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Stephen Brannan 2024-02-08Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Stephen Brannan 2024-02-08Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Stephen Brannan 2024-02-09Form 42024-02-120000950170-24-013959Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Andrew Miller 2024-02-09Form 42024-02-120000950170-24-013962Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Steven Paul 2024-02-09Form 42024-02-120000950170-24-013963Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Stephen Brannan 2024-02-13Form 42024-02-150000950170-24-015967Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Bill Meury 2024-02-13Form 42024-02-150000950170-24-015952Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Andrew Miller 2024-02-13Form 42024-02-150000950170-24-015958Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Jason Parker Brown 2024-02-13Form 42024-02-150000950170-24-015963Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Jason Parker Brown 2024-02-13Form 42024-02-150000950170-24-015963Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, William P. Kane Jr 2024-02-13Form 42024-02-150000950170-24-015972Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Steven Paul 2024-02-23Form 42024-02-260000950170-24-020397Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Steven Paul 2024-02-23Form 42024-02-260000950170-24-020397Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Steven Paul 2024-02-23Form 42024-02-260000950170-24-020397Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Steven Paul 2024-02-23Form 42024-02-260000950170-24-020397Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Steven Paul 2024-02-29Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Steven Paul 2024-03-01Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Steven Paul 2024-03-01Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Steven Paul 2024-03-01Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Steven Paul 2024-03-01Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Steven Paul 2024-03-04Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Steven Paul 2024-03-04Form 42024-03-040000950170-24-024999Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Stephen Brannan 2024-03-08Form 42024-03-110000950170-24-029406Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Stephen Brannan 2024-03-18Form 42024-03-180001140361-24-013922Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Christopher J. Coughlin 2024-03-18Form 42024-03-180001140361-24-013924Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Christopher J. Coughlin 2024-03-18Form 42024-03-180001140361-24-013924Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Christopher J. Coughlin 2024-03-18Form 42024-03-180001140361-24-013924Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Christopher J. Coughlin 2024-03-18Form 42024-03-180001140361-24-013924Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Christopher J. Coughlin 2024-03-18Form 42024-03-180001140361-24-013924Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Christopher J. Coughlin 2024-03-18Form 42024-03-180001140361-24-013924Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Denice Torres 2024-03-18Form 42024-03-180001140361-24-013934Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Denice Torres 2024-03-18Form 42024-03-180001140361-24-013934Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Denice Torres 2024-03-18Form 42024-03-180001140361-24-013934Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Denice Torres 2024-03-18Form 42024-03-180001140361-24-013934Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Laurie Olson 2024-03-18Form 42024-03-180001140361-24-013931Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Laurie Olson 2024-03-18Form 42024-03-180001140361-24-013931Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Laurie Olson 2024-03-18Form 42024-03-180001140361-24-013931Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Laurie Olson 2024-03-18Form 42024-03-180001140361-24-013931Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, William P. Kane Jr 2024-03-18Form 42024-03-180001140361-24-013927Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, William P. Kane Jr 2024-03-18Form 42024-03-180001140361-24-013927Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, William P. Kane Jr 2024-03-18Form 42024-03-180001140361-24-013927Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, William P. Kane Jr 2024-03-18Form 42024-03-180001140361-24-013927Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Bill Meury 2024-03-18Form 42024-03-180001140361-24-013928Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Bill Meury 2024-03-18Form 42024-03-180001140361-24-013928Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Bill Meury 2024-03-18Form 42024-03-180001140361-24-013928Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Bill Meury 2024-03-18Form 42024-03-180001140361-24-013928Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Jason Parker Brown 2024-03-18Form 42024-03-180001140361-24-013923Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Andrew Miller 2024-03-18Form 42024-03-180001140361-24-013930Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Steven Paul 2024-03-18Form 42024-03-180001140361-24-013933Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, James Healy 2024-03-18Form 42024-03-180001140361-24-013925Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Jeffrey M. Jonas 2024-03-18Form 42024-03-180001140361-24-013926Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Laurie Olson 2024-03-18Form 42024-03-180001140361-24-013931Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Atul Pande 2024-03-18Form 42024-03-180001140361-24-013932Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Atul Pande 2024-03-18Form 42024-03-180001140361-24-013932Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Atul Pande 2024-03-18Form 42024-03-180001140361-24-013932Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Atul Pande 2024-03-18Form 42024-03-180001140361-24-013932Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Atul Pande 2024-03-18Form 42024-03-180001140361-24-013932Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Denice Torres 2024-03-18Form 42024-03-180001140361-24-013934Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, David E. Wheadon 2024-03-18Form 42024-03-180001140361-24-013935Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, David E. Wheadon 2024-03-18Form 42024-03-180001140361-24-013935Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, David E. Wheadon 2024-03-18Form 42024-03-180001140361-24-013935Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, David E. Wheadon 2024-03-18Form 42024-03-180001140361-24-013935Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, David E. Wheadon 2024-03-18Form 42024-03-180001140361-24-013935Insider equity transaction reported since the proxy statement. Filing ↗
184Section 06, 2023 voteForm 8-K2023-06-210000950170-23-029140Item 5.07 · say-on-pay result. As reported: 65.16% (votes for as printed: 20,307,726). Filing ↗
185Section 06, 2022 voteForm 8-K2022-06-210001193125-22-177034Item 5.07 · say-on-pay result. As reported: 78.93% (votes for as printed: 21,124,063). Filing ↗
186Section 06, 2020 voteForm 8-K2020-06-170001193125-20-171354Item 5.07 · say-on-pay result. As reported: —. Filing ↗
187Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
188Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
189Section 09b board cost (computed)Computed——Cash 401,292 + equity 0 + all other 0 = 401,292, summed across the director compensation table rows.machine: formula: Σ = 401,292
190TG Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001437749-26-014233CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. Filing ↗machine: r4 · c24 · span 404551–404561
191Rhythm Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-290001628280-26-028375CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074
192Biohaven Pharmaceutical Holding Company Ltd., Section 10b CEO totalDEF 14A2026-03-130001935979-26-000028CEO total compensation as printed in Biohaven Pharmaceutical Holding Company Ltd.'s own proxy. As printed: 13,500,438. Filing ↗machine: r3 · c21 · span 423429–423439
193Mirati Therapeutics, Inc., Section 10b CEO totalDEF 14A2023-04-060001628280-23-011004CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. Filing ↗machine: r2 · c45 · span 540567–540577
194Cerevel Therapeutics Holdings, Inc., Section 10b CEO totalDEF 14A2023-04-280000950170-23-015766CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016
195Karuna Therapeutics (subject), Section 10b CEO totalDEF 14A2023-04-270000950170-23-014979CEO total compensation as printed in Karuna Therapeutics's own proxy. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694
196Apellis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
197Axsome Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
198Intra-Cellular Therapies, Inc., Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
199Acadia Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗
200Sage Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240000950170-25-058060CEO total compensation as printed in Sage Therapeutics, Inc.'s own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793
201Arvinas, Inc., Section 10b CEO totalDEF 14A2026-04-290001628280-26-028156CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930
202Allakos Inc., Section 10b CEO totalDEF 14A2024-04-230000950170-24-047043CEO total compensation as printed in Allakos Inc.'s own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107
203Prothena Corporation plc, Section 10b CEO totalDEF 14A2026-03-270001559053-26-000012CEO total compensation as printed in Prothena Corporation plc's own proxy. As printed: 5,896,045. Filing ↗machine: r3 · c27 · span 627016–627025
204Denali Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
205Kodiak Sciences Inc., Section 10b CEO totalDEF 14A2026-04-220001193125-26-170429CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068
206Alector, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
207Section 10a, Prothena Corporation plc reciprocityDEF 14A—0001559053-26-000012Prothena Corporation plc's most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
208Section 10a, Biohaven Pharmaceutical Holding Company Ltd. reciprocityDEF 14A—0001935979-26-000028Biohaven Pharmaceutical Holding Company Ltd.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
209Section 10a, Acadia Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-174163Acadia Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
210Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocityDEF 14A—0000950170-23-015766Cerevel Therapeutics Holdings, Inc. names Karuna Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
211Section 10a, Axsome Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
212Section 10a, Rhythm Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-028375Rhythm Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
213Section 10a, Apellis Pharmaceuticals, Inc. reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
214Section 10a, Intra-Cellular Therapies, Inc. reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
215Section 10a, Alector, Inc. reciprocityDEF 14A—0001193125-26-186928Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
216Section 10a, Allakos Inc. reciprocityDEF 14A—0000950170-24-047043Allakos Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
217Section 10a, Arvinas, Inc. reciprocityDEF 14A—0001628280-26-028156Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
218Section 10a, Denali Therapeutics Inc. reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
219Section 10a, Kodiak Sciences Inc. reciprocityDEF 14A—0001193125-26-170429Kodiak Sciences Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
220Section 10a, Mirati Therapeutics, Inc. reciprocityDEF 14A—0001628280-23-011004Mirati Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
221Section 10a, Sage Therapeutics, Inc. reciprocityDEF 14A—0000950170-25-058060Sage Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗
222Section 10a, TG Therapeutics, Inc. reciprocityDEF 14A—0001437749-26-014233TG Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Karuna Therapeutics. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.